Several other equities research analysts have also commented on EIGR. Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a hold rating to a buy rating and set a $16.00 price target for the company in a report on Monday, April 1st. Wedbush reduced their price target on shares of Eiger Biopharmaceuticals from $43.00 to $35.00 and set an outperform rating for the company in a report on Wednesday, April 24th. Finally, BidaskClub lowered shares of Eiger Biopharmaceuticals from a buy rating to a hold rating in a report on Monday, February 25th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $30.88.
NASDAQ:EIGR opened at $11.10 on Friday. Eiger Biopharmaceuticals has a one year low of $8.20 and a one year high of $18.00. The company has a debt-to-equity ratio of 0.38, a current ratio of 10.16 and a quick ratio of 10.16. The stock has a market capitalization of $213.79 million, a PE ratio of -2.91 and a beta of 1.48.
In other news, Director Thomas John Dietz acquired 5,000 shares of the business’s stock in a transaction dated Monday, April 22nd. The shares were purchased at an average price of $11.05 per share, with a total value of $55,250.00. Following the transaction, the director now directly owns 15,000 shares in the company, valued at $165,750. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders bought 7,477 shares of company stock worth $83,338. Insiders own 7.90% of the company’s stock.
Several institutional investors have recently modified their holdings of EIGR. RA Capital Management LLC purchased a new position in shares of Eiger Biopharmaceuticals in the 4th quarter worth approximately $24,541,000. 683 Capital Management LLC grew its position in Eiger Biopharmaceuticals by 155.1% during the 4th quarter. 683 Capital Management LLC now owns 1,610,529 shares of the biotechnology company’s stock worth $16,363,000 after purchasing an additional 979,296 shares during the last quarter. BlackRock Inc. grew its position in Eiger Biopharmaceuticals by 108.6% during the 4th quarter. BlackRock Inc. now owns 468,678 shares of the biotechnology company’s stock worth $4,761,000 after purchasing an additional 244,028 shares during the last quarter. Fosun International Ltd purchased a new stake in Eiger Biopharmaceuticals during the 4th quarter worth approximately $1,694,000. Finally, Broadfin Capital LLC purchased a new stake in Eiger Biopharmaceuticals during the 4th quarter worth approximately $1,456,000. 78.57% of the stock is currently owned by hedge funds and other institutional investors.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Recommended Story: Catch-Up Contributions
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.